Login to Your Account



Financings Roundup

Relypsa Loads $80M Series C to Fund Patiromer Phase III

By Marie Powers
Staff Writer

Thursday, August 16, 2012

Relypsa Inc. moved patiromer (RLY5016), its high-capacity nonabsorbed oral potassium binder, closer to the finish line in hyperkalemia by closing an $80 million Series C preferred stock financing to fund pivotal Phase III trials and submission of a new drug application (NDA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription